Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

A real-world evidence (RWE) retrospective review from UK hospital patient records

MANCHESTER (SALFORD): 164 patients from a tertiary centre, review at 3 and 6 months2,3

The DUPIXENT safety and tolerability profile is consistent in adults and adolescents aged 12 years or older with moderate-to-severe AD1

Adverse reactions for DUPIXENT in clinical trials and post-marketing experience*1


SYSTEM ORGAN CLASS FREQUENCY ADVERSE REACTION
Infections and infestations ≥1% to <10% Conjunctivitis, oral herpes
Blood and lymphatic system disorders ≥1% to <10% Eosinophilia
Immune system disorders <0.01% Serum sickness/serum sickness-like reactions
Not known Anaphylactic reaction, Angiodema
Nervous system disorders ≥1% to <10% Headache
Eye disorders ≥1% to <10% Conjunctivitis allergic, eye pruritus, blepharitis
≥0.1% to 1% Keratitis, Ulcerative keratitis
Musculoskeletal and connective tissue disorders Not known Arthralgia
General disorders and administration site conditions Not known Injection site reactions
MANCHESTER (SALFORD)3
(N=164)
Adverse event n (%)
Eye symptoms 66 (44.30)
Sicca 36 (23.07)
Conjunctivitis 25 (16.02)
Facial erythema 10 (6.41)
MSK 6 (3.84)
Alopecia areata 5 (3.20)
Eczema herpeticum 1 (0.64)
Vasovagal episodes 3 (1.92)
Injection site reaction 2 (1.31)
Pneumonia 1 (0.64)
Flu like symptoms 1 (0.64)
MANCHESTER (SALFORD)3
(N=164)
Discontinuation n (%)
Total discontinuation 12 (7.8)
Treatment failure 2 (1.28)
Severe conjunctivitis 3 (1.92)
Alopecia areata 1 (0.64)
Pregnancy 2 (1.28)
Vasovagal episode 1 (0.64)
Mode of administration 1 (0.64)
Lost to follow-up 2 (1.28)

*Pooled data from placebo-controlled monotherapy clinical studies and placebo-controlled concomitant therapy with TCS study; patients exposed to DUPIXENT 300 mg QW or 300 mg Q2W.1
From post-marketing reporting.


AEs, adverse events; AD, atopic dermatitis; MSK, musculoskeletal; QW, once weekly; Q2W, once every two weeks; TCS, topical corticosteroids.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. Kreeshan F.C, et al. Real-world experience of dupilumab for patients with moderate-to-severe atopic dermatitis in a tertiary care setting (Abstract P095) presented at the 100th British Association of Dermatology, Virtual Congress, September 1 2020.
  3. Kreeshan F.C, et al. Real-world experience of dupilumab for patients with moderate-to-severe atopic dermatitis in a tertiary care setting (Poster P095) presented at the 100th British Association of Dermatology, Virtual Congress, September 1 2020.